Presentations:
16.30 - 17.00 - Introduction and background to the prebiotic concept - Prof. Glenn Gibson, University of Reading (UK)
This presentation briefly described the history of prebiotics and give latest definitions. It described the criteria needed for a prebiotic effect and give examples of use. Health outcomes were discussed, principally in the areas of mineral absorption and infant health.
To download the presentation, click here.
17.00 - 17.30 - Prebiotics and gastrointestinal disorders - Dr. Kevin Whelan, King's College London (UK)
Evidence has shown that prebiotics may stimulate the growth of gastrointestinal bifidobacteria, and some other immuno-regulatory bacteria, as well as altering gastrointestinal fermentation. This presentation reviewed these effects in the context of gastrointestinal disorders, and the clinical trials of prebiotics in irritable bowel syndrome and inflammatory bowel disease will be reviewed.
To download the presentation, click here.
17.30 - 18.00 - Prebiotics and obesity-related diseases - Prof. Nathalie Delzenne, Catholic University of Louvain (BE)
This presentation focussed on the experimental and human data suggesting a role of prebiotic approach in the control of food intake and body weight, but also in the control of metabolic disorders associated with obesity (systemic inflammation, hepatic steatosis and inflammation, adipogenesis, gut permeability)
To download the presentation, click here.
18.00 - 18.30 - Prebiotics and Cancer - Prof. Ian Rowland, University of Reading (UK)
Studies in animal models, suggest that prebiotics can suppress tumour induction and development. Potential mechanisms include changes in gut bacterial enzyme activities, upregulation of apoptosis and induction of protective enzymes. A pre+probiotics study in human subjects, combining probiotics and prebiotics and using putative biomarkers of cancer risk showed improvements in some, including a reduction in DNA damage and cell proliferation in colon biopsies.
To download the presentation, click here.